Answers are grounded in this paper and cite their sources.
Probiotic candidates require rigorous strain-level safety assessments prior to functional food applications because safety-relevant properties are not universally conserved across strains within the same species. The aim of this study was to evaluate the safety of Levilactobacillus brevis KU15151 in accordance with Food and Agriculture Organization/World Health Organization, European Food Safety Authority (EFSA), and Korean Ministry of Food and Drug Safety guidelines, through phenotypic assays and whole-genome-based analyses. The minimum inhibitory concentrations for all eight evaluated antibiotics were within the EFSA-established cut-off values, and no acquired resistance genes were detected using ResFinder. Phenotypic assessments confirmed the absence of β-hemolytic activity, mucin degradation, gelatin liquefaction, urease activity, indole production, β-glucuronidase activity, bile salt deconjugation, and cytotoxicity towards Caco-2 intestinal epithelial cells at a multiplicity of infection of 250. D- and L-lactic acids were produced at approximately equimolar concentrations, which is consistent with heterofermentative metabolism. Among the eight assessed biogenic amines, only tyramine was detected (79.26 ppm), at less than the published food safety thresholds. VirulenceFinder did not identify any virulence-associated genes. Collectively, these findings suggest that L. brevis KU15151 satisfies the principal safety criteria under the examined conditions, supporting its potential as a probiotic candidate for in vivo validation.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: